UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2022, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form 8-K.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Intellia Therapeutics, Inc. |
|
|
|
|
Date: |
November 3, 2022 |
By: |
/s/ John M. Leonard |
|
|
|
Name: John M. Leonard |
Exhibit 99.1
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
CAMBRIDGE, Mass., Nov. 3, 2022 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2022.
“During the most recent quarter, Intellia achieved significant clinical milestones across two landmark first-in-human studies,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We believe the latest data from our lead in vivo program, NTLA-2001, indicate it has the potential to set a new standard for how people living with ATTR amyloidosis are treated for this life-threatening disease. We are rapidly completing the dose-expansion portion of the study and are engaging with regulatory agencies, including in the U.S., as we move closer to a global, pivotal trial. Interim data from our second in vivo program, NTLA-2002, demonstrated robust reductions in both plasma kallikrein levels and the rate of swelling attacks in patients with hereditary
Page 1 of 9 |
intelliatx.com |
angioedema. These initial data support the potential for a single dose of NTLA-2002 to permanently prevent the debilitating and potentially fatal HAE attacks that characterize this lifelong genetic disease. We look forward to presenting additional data from both NTLA-2001 and NTLA-2002 later this month.”
Dr. Leonard continued, “Together, these interim datasets demonstrate the modularity of our CRISPR-based platform, providing powerful evidence of our ability to apply this technology broadly to address a wide range of diseases. Beyond gene knockout programs, we are advancing our first in vivo insertion candidate, NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency, with plans to submit a regulatory filing next year.”
Third Quarter 2022 and Recent Operational Highlights
In Vivo Program Updates
Transthyretin (ATTR) Amyloidosis
Page 2 of 9 |
intelliatx.com |
Hereditary Angioedema (HAE)
Page 3 of 9 |
intelliatx.com |
Alpha-1 Antitrypsin Deficiency (AATD)
Ex Vivo Program Updates
CD30+ Lymphomas
Research and Corporate Updates
Page 4 of 9 |
intelliatx.com |
Upcoming Events
The Company will participate in the following events during the fourth quarter of 2022:
Upcoming Milestones
The Company has set forth the following for pipeline progression:
In Vivo
Page 5 of 9 |
intelliatx.com |
Third Quarter 2022 Financial Results
Conference Call to Discuss Third Quarter 2022 Results
The Company will discuss these results on a conference call today, Thursday, November 3, at 8 a.m. ET.
To join the call:
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at intelliatx.com, beginning on November 3, at 12 p.m. ET.
Page 6 of 9 |
intelliatx.com |
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatx.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: its ability to successfully extend its leadership position and harness the full potential of genomic medicines to bolster its genome editing capabilities and pipeline; the safety, efficacy, success and advancement of its clinical programs for NTLA-2001 for the treatment of ATTR amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (“HAE”) pursuant to its clinical trial applications (“CTA”), including the expected timing of data releases, regulatory filings, and the initiation, enrollment, dosing, and completion of clinical trials, such as the completion of planned enrollment of Phase 1 study for NTLA-2001; its ability to select a dose to advance to a pivotal study for NTLA-2001; the advancement of development candidates, such as NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (“AATD”)-associated lung disease, NTLA-2003 for AATD-associated liver disease and NTLA-6001 for CD30+ lymphomas, including the success of its IND-enabling studies; its ability to generate data to initiate clinical trials and the timing of CTA and IND submissions, including the submission of an IND or IND-equivalent for NTLA-3001 in 2023; the expansion of its CRISPR/Cas9 technology and related technologies to advance additional development candidates and timing expectations of advancing such development candidates and releasing data related to such technologies and development candidates; its ability to optimize the impact of its collaborations on its development programs, including, but not limited to, its collaboration with Regeneron Pharmaceuticals, Inc. and their co-development program for ATTR amyloidosis; and growth as a Company and expectations regarding its uses of capital, expenses, future accumulated deficit and financial results.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to
Page 7 of 9 |
intelliatx.com |
differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of preclinical and clinical studies and other development requirements for its product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; risks related to the ability to develop and commercialize any one or more of Intellia’s product candidates successfully; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; risks related to the potential impact of the coronavirus disease pandemic, including the impact of any variants, on strategy, future operations and timing of its clinical trials; and risks related to Intellia’s collaborations with Regeneron Pharmaceuticals, Inc. or its other collaborations not continuing or not being successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission (“SEC”). All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
INTELLIA THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Amounts in thousands, except per share data)
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Collaboration revenue |
$ |
13,266 |
|
|
$ |
7,204 |
|
|
$ |
38,548 |
|
|
$ |
20,199 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Research and development |
|
96,651 |
|
|
|
60,486 |
|
|
|
319,945 |
|
|
|
158,646 |
|
|||
|
General and administrative |
|
22,145 |
|
|
|
18,711 |
|
|
|
66,680 |
|
|
|
48,988 |
|
|||
|
|
Total operating expenses |
|
118,796 |
|
|
|
79,197 |
|
|
|
386,625 |
|
|
|
207,634 |
|
||
Operating loss |
|
(105,530 |
) |
|
|
(71,993 |
) |
|
|
(348,077 |
) |
|
|
(187,435 |
) |
||||
Other (expense) income, net: |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Interest income |
|
1,945 |
|
|
|
349 |
|
|
|
3,188 |
|
|
|
780 |
|
|||
|
Loss from equity method investment |
|
(1,834 |
) |
|
|
- |
|
|
|
(7,831 |
) |
|
|
- |
|
|||
|
Change in fair value of contingent consideration |
|
(7,810 |
) |
|
|
- |
|
|
|
(8,059 |
) |
|
|
- |
|
|||
|
|
Total other (expense) income, net |
|
(7,699 |
) |
|
|
349 |
|
|
|
(12,702 |
) |
|
|
780 |
|
||
Net loss |
$ |
(113,229 |
) |
|
$ |
(71,644 |
) |
|
$ |
(360,779 |
) |
|
$ |
(186,655 |
) |
||||
Net loss per share, basic and diluted |
$ |
(1.49 |
) |
|
$ |
(0.97 |
) |
|
$ |
(4.78 |
) |
|
$ |
(2.68 |
) |
||||
Weighted average shares outstanding, basic and diluted |
|
76,047 |
|
|
|
73,706 |
|
|
|
75,543 |
|
|
|
69,720 |
|
||||
Page 8 of 9 |
intelliatx.com |
INTELLIA THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEET DATA (UNAUDITED)
(Amounts in thousands)
|
|
September 30, |
|
|
December 31, |
|
||
Cash, cash equivalents and marketable securities |
|
$ |
848,727 |
|
|
$ |
1,086,049 |
|
Total assets |
|
|
1,084,458 |
|
|
|
1,294,464 |
|
Total liabilities |
|
|
259,507 |
|
|
|
254,220 |
|
Total stockholders' equity |
|
|
824,951 |
|
|
|
1,040,244 |
|
Intellia Contacts:
Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
+1-857-449-4175
ian.karp@intelliatx.com
Lina Li
Senior Director, Investor Relations and Corporate Communications
+1-857-706-1612
lina.li@intelliatx.com
Media:
Rebecca Spalding
Ten Bridge Communications
+1-646-509-3831
media@intelliatx.com
rebecca@tenbridgecommunications.com
Page 9 of 9 |
intelliatx.com |